Literature DB >> 35160196

The Validity of the SQoL-18 in Patients with Bipolar and Depressive Disorders: A Psychometric Study from the PREMIUM Project.

Laurent Boyer1, Sara Fernandes1, Melanie Faugere1, Raphaelle Richieri2, Pascal Auquier1, Guillaume Fond1,2, Christophe Lancon1,2.   

Abstract

The S-QoL 18 is a self-administered questionnaire that assesses quality of life (QoL) among individuals with schizophrenia. This study aims to validate the S-QoL 18 in bipolar and depressive disorders for a more widespread use in psychiatric settings. This study was conducted in a non-selected sample of individuals with bipolar and depressive disorders in the day hospital of a regional psychiatric academic hospital. Two-hundred and seventy-two stable outpatients with bipolar (n = 73) and recurrent and persistent depressive (n = 199) disorders were recruited over a 12 month-period. The S-QoL 18 was tested for construct validity, reliability, and external validity. The eight-factor structure of the S-QoL 18 was confirmed by confirmatory factor analysis (RMSEA = 0.075 (0.064-0.086), CFI = 0.972, TLI = 0.961). Internal consistency and reliability were satisfactory. External validity was confirmed via correlations between S-QoL 18 dimension scores, symptomatology, and functioning. The percentage of missing data for the eight dimensions did not exceed 5%. INFIT statistics were ranged from 0.7 to 1.2, ensuring that all items of the scale measured the same QoL concept. In conclusion, the S-QoL 18 appears to be a valid and reliable instrument for measuring QoL in patients with bipolar and depressive disorders. The S-QoL 18 may be used by healthcare professionals in clinical settings to accurately assess QoL in individuals with bipolar and depressive disorders, as well as in schizophrenia.

Entities:  

Keywords:  bipolar and depressive disorders; bipolar disorders; depressive disorders; health services research; mental health; psychiatry; quality of life; schizophrenia

Year:  2022        PMID: 35160196      PMCID: PMC8836740          DOI: 10.3390/jcm11030743

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  48 in total

Review 1.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Authors:  Harvey A Whiteford; Louisa Degenhardt; Jürgen Rehm; Amanda J Baxter; Alize J Ferrari; Holly E Erskine; Fiona J Charlson; Rosana E Norman; Abraham D Flaxman; Nicole Johns; Roy Burstein; Christopher J L Murray; Theo Vos
Journal:  Lancet       Date:  2013-08-29       Impact factor: 79.321

2.  Cronbach's alpha.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1997-02-22

3.  Comparative fit indexes in structural models.

Authors:  P M Bentler
Journal:  Psychol Bull       Date:  1990-03       Impact factor: 17.737

4.  Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder.

Authors:  Ludovic Samalin; Laurent Boyer; Andrea Murru; Isabella Pacchiarotti; María Reinares; Caterina Mar Bonnin; Carla Torrent; Norma Verdolini; Corinna Pancheri; Ingrid de Chazeron; Mohamed Boucekine; Pierre-Alexis Geoffroy; Frank Bellivier; Pierre-Michel Llorca; Eduard Vieta
Journal:  J Affect Disord       Date:  2017-01-03       Impact factor: 4.839

5.  A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF).

Authors:  S H Jones; G Thornicroft; M Coffey; G Dunn
Journal:  Br J Psychiatry       Date:  1995-05       Impact factor: 9.319

6.  Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.

Authors:  Guillaume Fond; Laurent Boyer; Mohamed Boucekine; Latif A Aden; Franck Schürhoff; Arnaud Tessier; Meja Andrianarisoa; Fabrice Berna; Lore Brunel; Delphine Capdevielle; Isabelle Chereau; Jasmina Mallet; Hélène Denizot; Jean Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Romain Rey; Raphaelle Richieri; Christine Passerieux; Aurélie Schandrin; Mathieu Urbach; Pierre Vidailhet; Pierre Michel Llorca; David Misdrahi
Journal:  Schizophr Res       Date:  2016-10-24       Impact factor: 4.939

7.  Evaluating the impact of a quality of life assessment with feedback to clinicians in patients with schizophrenia: randomised controlled trial.

Authors:  Laurent Boyer; Christophe Lançon; Karine Baumstarck; Nathalie Parola; Julie Berbis; Pascal Auquier
Journal:  Br J Psychiatry       Date:  2013-05-09       Impact factor: 9.319

8.  Making sense of Cronbach's alpha.

Authors:  Mohsen Tavakol; Reg Dennick
Journal:  Int J Med Educ       Date:  2011-06-27

9.  Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices.

Authors:  Karine Baumstarck; Mohamed Boucekine; Laurent Boyer; Valérie Aghababian; Nathalie Parola; Françoise Reuter; Anderson Loundou; Christophe Lançon; Jean Pelletier; Pascal Auquier
Journal:  BMC Neurol       Date:  2014-04-08       Impact factor: 2.474

Review 10.  Multi-Level Processes and Retina-Brain Pathways of Photic Regulation of Mood.

Authors:  Julia Maruani; Pierre A Geoffroy
Journal:  J Clin Med       Date:  2022-01-16       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.